Vaccination with a MHC Class II Peptide Attenuates Cellular and Humoral Responses against t AChR and Suppresses Clinical EAMG

  title={Vaccination with a MHC Class II Peptide Attenuates Cellular and Humoral Responses against t AChR and Suppresses Clinical EAMG},
  author={Minako Oshima and Philip R. Deitiker and Tetsuo Ashizawa and M. Zouhair Atassi},
  pages={183 - 190}
An animal model of myasthenia gravis (MG), termed experimental autoimmune MG (EAMG), can be induced in C57BL/6 (B6, H-2 b ) mice by immunization with Torpedo californica acetylcholine receptor ( t AChR). We have investigated the effect of vaccination with MHC class II peptide I-A g b 62-76 on clinical EAMG and on T cell and antibody (Ab) responses against t AChR. B6 mice were vaccinated with the peptide (25 w g/mouse) four times prior to two injections with t AChR. The incidence of clinical… Expand
Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice
The treatment greatly reduced the occurrence and severity of clinical MG relative to controls that received saline/Alum+PT or none and it also reduced antibody and T-cell responses against tAChR. Expand
Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients
The results indicate that the function of disease-related MHC alleles may be blocked by directly and selectively targeting the antigen-presenting region on these MHC molecules and suggest that DQ molecules are one of those involved in the restriction of autoimmune anti-AChR responses in MG. Expand
Injection of inactive Bordetella pertussis and complete Freund’s adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice
The combined use of CFA and iBP significantly increased both the occurrence and severity of clinical MG in the immunized mice, accompanied by higher antibody (Ab) and T-cell responses to tAChR. Expand
Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice
The results indicate that anti-tAChR autoimmune response alone can reduce bone density in EAMG mice, suggesting that BMD decrease can occur even when muscle activity is normal. Expand
The Current Status of Human Anti-Cancer Vaccines
Therapeutic cancer vaccines (or active immunotherapy) aim to guide the patient's personal immune system to eradicate cancer cells, represented by a greater capacity to selectively eradicate the modified cells, thus triggering lower toxicity and the capacity to identify and invade multiple target molecules. Expand
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials, as well as highlighting the importance of combining immunotherapy with conventional therapies such as radiation and chemotherapy. Expand


Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
Preliminary results would suggest that immunization with the MHC peptide might be employed for control of the autoimmune disease. Expand
Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies.
The in vitro cellular reactivity to AChR in experimental autoimmune myasthenia gravis (EAMG) mice (C57Bl/6) was suppressed by monoclonal anti-I-Ab antibodies directed against private (Ia20) or public (IA8) specificities, suggesting a critical role for these Ia determinants in the cellular immune response to A ChR in murine EAMG. Expand
An immunodominant site of acetylcholine receptor in experimental myasthenia mapped with T lymphocyte clones and synthetic peptides.
T cell populations and T cell hybridoma clones were generated and tested their reactivity to synthetic uniform-sized overlapping peptides representing the entire extracellular portion of the alpha-chain of the AChR, and the predominant reactivity of the T cell clones and the parent lines was to a peptide corresponding to residues 146-162 of Torpedo A chR. Expand
Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope
Results indicated that blocking the function of disease-related MHC by targeting a disease-associated region on MHC molecules could be an effective, straightforward and feasible strategy for immunointervention in MG. Expand
A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitis.
Vaccination of SJL/J mice with an 18-amino acid synthetic peptide from the third hypervariable region of the murine class II MHC IAs beta chain is capable of eliciting auto-anti-IAs antibodies specific for the IAs Beta chain and preventing and treating EAE. Expand
B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor.
T alpha 146-162-specific T cells, although unable to recognize m alpha 146 -162, are nevertheless pathogenic because they help B cells responding to a tAChR region that is conserved in mAChr and involved in ACh binding. Expand
Profile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor.
The presence of persistent T cell responses to the second half of the main extracellular domain of the alpha chain is associated with the development of EAMG in B6 mice, while absence of these responses in SJL mice may enable them to escape the disease. Expand
Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide.
The results indicate that the mPEG-Ac ChoR alpha-(125-148) conjugate has epitope-specific tolerogenicity for antibody responses in EAMG and that the AcChoR alpha-subunit region comprising residues 125-148 plays an important pathophysiological role in EamG. Expand
Experimental myasthenia gravis. A murine system
Myasthenia in the mouse does not occur simply as a consequence of the presence of antibodies directed against cell surface antigenic determinants of AChR, and these studies suggest that populations of a particular structure and/or specificity are required. Expand
Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit
The results suggest that the pathogenesis of this autoimmune disease is variable at the cellular‐molecular level, and other regulatory influences may play important roles in the triggering of the autoimmune responses. Expand